Cardiac Assessment by PV Loop in IPAH and Scleroderma PAH

Scleroderma Clinical Trial

— CALIPSO  

Official title:

Understanding Right Ventricular Heart Failure in Scleroderma and Idiopathic Pulmonary Arterial Hypertension

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04610788
• Other study ID #: NA_00049022
• Secondary ID: R01HL114910-06
• Status: Recruiting
• Start date: April 15, 2019
• Est. completion date: December 31, 2024

Study information

• Verified date: January 2024
• Source: Johns Hopkins University
• Contact: Paul Hassoun, MD
• Phone: 410 614 6311
• Email: phassou1[@]jhmi.edu
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This observational study is being done to understand why people with scleroderma can develop pulmonary arterial hypertension (high blood pressure in the lungs, abbreviated PAH) and a weak heart muscle (heart failure). The study will also help the investigators understand why people with PAH from an unknown cause (called idiopathic PAH, or IPAH) can also develop a weakened heart muscle. The response of the right side of the heart or right ventricle (RV) to standard PAH therapy in scleroderma-associated PAH and in IPAH will be assessed. Blood and tissue samples will be collected from research participants during participants' normal standard of care procedures. People with scleroderma-associated PAH or idiopathic cause (IPAH) who need a right heart catheterization may join this study.

Description:

Patients with scleroderma associated pulmonary hypertension (with or without interstitial lung disease) have a worse prognosis compared to patients with idiopathic pulmonary arterial hypertension (IPAH). The investigators have discovered through a previous protocol that patients with scleroderma associated pulmonary hypertension (SSc-PAH) have intrinsic right ventricular (RV) contractile dysfunction compared with patients with idiopathic pulmonary hypertension (IPAH) despite similar afterload imposed by the pulmonary vasculature. Patients with scleroderma or presumed/known IPAH who are clinically referred for right heart catheterization (RHC) will undergo, in addition to a clinically indicated RHC, state-of-the-art Pressure-Volume (P/V) Loop Assessment and RV biopsy for research purposes. The investigators will also do a standard pathologic assessment of the RV tissue (H&E, special staining, electron microscopy), microvascular density measurements using immunohistochemistry techniques and isolated skinned myocyte experiments. Additional experiments will include proteomics, genomics/genetics, and RV protein and microRNA expression. The investigators will compare these findings in both groups (IPAH and SSc-PAH), before and after standard treatment for 6 months, in order to fully understand the differences in how the RV adapts to pressure overload and reasons for impaired RV function in SSc-PAH as well as identifying potential therapeutic targets.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 100
• Est. completion date: December 31, 2024
• Est. primary completion date: December 31, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 100 Years

Eligibility

Inclusion Criteria:

• Patients 18 years or older with clinically diagnosed scleroderma or presumed/known idiopathic pulmonary hypertension.

Exclusion Criteria:

• Patients found to have secondary pulmonary hypertension (PH due to left heart failure) on clinical RHC.

• Hemodynamically unstable patients (systolic blood pressure < 90mmHg, vasopressor requirement).

• Patients whom are unable to give consent for themselves.

• Patients with RV clot or septal aneurysm will be excluded.

• In order to undergo the clinical right heart catheterization procedures, pregnancy testing (urine or serum) is standard of care.

• Pregnancy

Related Conditions & MeSH terms

• Hypertension
• Pulmonary Arterial Hypertension
• Pulmonary Artery Hypertension
• Scleroderma
• Scleroderma, Diffuse
• Scleroderma, Localized
• Scleroderma, Systemic

Locations

Country	Name	City	State
United States	Johns Hopkins	Baltimore	Maryland

Sponsors (2)

Lead Sponsor	Collaborator
Johns Hopkins University	National Heart, Lung, and Blood Institute (NHLBI)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Right Ventricular Function as assessed by RHC	Assessed on the clinical RHC as normal, moderately reduced, or severely reduced.	Baseline
Primary	Change in pulmonary vascular resistance	Assessed as improved or decreased after 6 months by comparing the change in pulmonary vascular resistance in Wood units on the clinical RHC.	Baseline and 6months
Primary	Change in arterial elastance	Assessed as improved or decreased after 6 months by comparing the change in arterial elastance in pressure volume (PV) loops.	Baseline and 6 months
Primary	Change in myofilament contractility	Assessed as Normal or Abnormal after studying the collected samples in lab. Abnormal can be either reduced or increased; i.e. hyper- or hypo-contractile.	up to 4 years
Primary	Change in calcium sensitivity	Assessed as either increased- or decreased- sensitivity after 6 months, by studying the collected samples in lab.	up to 4 years
Secondary	Number of genes expressed	Gene expression as assessed by observing presence of microRNA in the lab.	up to 4 years
Secondary	Number of proteins expressed	Protein expression as assessed by observing post-translational modification of candidate proteins in the lab.	up to 4 years